Skip to main content

Brennan Aoife's Form 4 filing

Climb Bio, Inc. (CLYM) · filed Jun 30, 2026

Accession no.
0001193125-26-291131
Filed
Jun 30, 2026
Trade date
Jun 27-29, 2026
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $407.0K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Brennan AoifeCIK 0001714563Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 27, 2026Common StockMOption exerciseAcquired+68,750–F1–118,633Direct
Jun 29, 2026Common StockSSaleDisposed−30,902$13.17F4−$406,979.3487,731Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 27, 2026Common StockMOption exerciseDisposed−68,750$0.00$0137,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)